Prelude Highlights Continued Strength of Discovery Engine
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at...
Source: globenewswire.com
📰 Phase 1 Study News
Phase 1 Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Phase 1 Study. Real-time updates on events, politics, business and more.
FDA Clears Investigational New Drug Application for TCR-NK Cell Therapy in Multiple Myeloma
The FDA has issued a ‘safe to proceed’ for the investigational new drug application enabling a phase 1 study evaluating NY-ESO-1 TCR/IL-15 NK, a first-in-class engineered T-cell receptor natural killer cell therapy for patients with relapsed/refractory multiple myeloma.
United States Sally Cooper Murray Lachlan Mackinnon Adrian Woolfson Katy Rezvani Department Of Stem Cell Transplantation
Source: onclive.com
PHE855 Continues to Show High, Durable Responses in R/R Multiple Myeloma
Now that positive phase 1 results have been reported for PHE855, a phase 2 study of PHE855 is currently underway in patients with relapsed and refractory multiple myeloma.
United States Dana Farber Cancer Institute Adams Sperling Relapsed Or Refractory Multiple Myeloma Phase 1 Study Car Product
Source: targetedonc.com
IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors
Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.
United States Matthewh Taylor Providence Cancer Institute Melanoma Program Providence Cancer Institute Thyroid Program Developmental Cancer Therapeutics Laboratory Research Institute
Source: onclive.com
Pharma Stock News: Skye Bioscience (OTCQB: SKYE) Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion
Pharma Stock News: Skye Bioscience (OTCQB: SKYE) Receives Positive Safety Review of Third Cohort in Phase 1 Study of SBI-100 Ophthalmic Emulsion
United States San Diego Skye Bioscience Newswire Skye Bioscience Inc Exchange Commission Newsfile Corp Investorideas
Source: investorideas.com
Moderna Starts New COVID-19 Vaccine Trial
Moderna Starts New COVID-19 Vaccine Trial by Angela Mohan on March 17, 2021 at 2:17 PM First participants have been dosed in the Phase 1 study of mRNA-1283, Modernas next generation COVID-19 vaccine candidate, which will assess the safety and immunogenicity of mRNA-1283. "We are pleased to begin this Phase 1 study of our next generation COVID-19 vaccine candidate, mRNA-1283," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our investments in our mRNA platform hav...
Chief Executive Officer Receptor Binding Domain N Terminal Domain India Achieves Preferred Greeting Myths Debunkedcoronavirusindian Namaste
Source: medindia.net